Enveric Biosciences Inc
Change company Symbol lookup
Select an option...
ENVB Enveric Biosciences Inc
BKE Buckle Inc
ROP Roper Technologies Inc
ESYJY Easyjet PLC
OGE OGE Energy Corp
ASB-E Associated Banc-Corp
LI Li Auto Inc
IKT Inhibikase Therapeutics Inc
GSIT GSI Technology Inc
AZRE Azure Power Global Ltd
Go

Health Care : Pharmaceuticals | Small Cap Value
Company profile

Enveric Biosciences, Inc. is a biotechnology company. The Company is engaged in the development of novel small-molecule therapeutics for the treatment of anxiety, depression and addiction disorders. The Company through Psybrary has created a robust intellectual property (IP) portfolio of New Chemical Entities (NCEs) for specific mental health indications or physical ailments. The Company's lead program, EB-373, is a next-generation prodrug of psilocin, the active metabolite of psilocybin. EB-373 is a drug candidate from the EVM201 Series advancing through preclinical development for the treatment of anxiety disorders. The Company is also advancing its third generation of therapeutics, the EVM301 Series, that eliminates the psychedelic experience and removes unwanted effects, reducing safety concerns, and hence offering a novel and holistic approach for treating central nervous system disorders.

Premarket

Last Trade
Delayed
$4.16
0.2085 (5.28%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$3.95
Day's Change
0.00 (0.00%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)
Volume:
2,393

10-day average volume:
20,035,812
2,393

Warner Bros. Discovery forecasts steeper charges related to acquisition

6:37 pm ET December 14, 2022 (MarketWatch)
Print

Warner Bros. Discovery on Wednesday said it expected to take bigger charges related to its acquisition of AT&T's WarnerMedia, as it tries to pare down operations. The recently combined company - the parent of HBO, CNN and other channels - said in a filing that it expects pretax restructuring charges of $4.1 billion to $5.3 billion, including $2.8 billion to $3.5 billion of content-impairment and development write-offs. Those figures are up from prior estimates of $3.2 billion to $4.3 billion in restructuring charges, with content-impairment and development write-offs of roughly $2 billion to $2.5 billion. The exact reason for the increase was unclear, but it comes after the company's efforts to lower costs, including through layoffs and pulling back on programming, in the wake of the acquisition. Warner Bros. Discovery said it was not revising prior estimates on costs related to organizational restructuring - such as for severance from layoffs and relocation - or costs related to cash expenditures, consolidating facilities or terminating contracts. However, it said that the ongoing reorganization, still expected to largely wrap up by the end of 2024, "could result in additional impairments above the revised estimates." Shares were down 0.7% after hours.

-Bill Peters

	

(END) Dow Jones Newswires

December 14, 2022 18:37 ET (23:37 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.